Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 16/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR1D | P28221 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | HTR1B | P28222 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-258719 SCHEMBL2471089 | 1.00 | HTR7 (1.00) | HTR7DRD2HTR1DDRD3HTR1A | |
| Sb-258719 SCHEMBL2471088 | 1.00 | HTR7 (1.00) | HTR7DRD2HTR1DDRD3HTR1A | |
| Sb-258719 SCHEMBL3688509 | 0.99 | HTR7 (0.98) | HTR7DRD2HTR1DDRD3HTR1A | |
| SCHEMBL2729765 | 0.81 | HTR7 (0.74) | HTR7DRD2HTR1DDRD3HTR2A | |
| SCHEMBL14520856 | 0.80 | HTR7 (0.67) | HTR7DRD2HTR1DDRD3HTR1A | |
| SCHEMBL4456846 | 0.74 | HTR7 (0.58) | HTR7DRD2HTR1DDRD3CCR5 | |
| SCHEMBL5440416 | 0.72 | HTR7 (0.56) | HTR7DRD2HTR1DDRD3CCR5 | |
| SCHEMBL8595287 | 0.70 | HTR7 (0.54) | HTR7DRD2HTR1DDRD3HTR2A | |
| SCHEMBL14520864 | 0.70 | HTR7 (0.53) | HTR7DRD2HTR1DDRD3HTR2A | |
| Sb-258741 SCHEMBL4454954 | 0.69 | HTR7 (1.00) | HTR7DRD2HTR1DDRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558412-B2 | Vaccination of immunocompromised subjects | Seqirus UK Limited (GB) | 2026-02-24 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250269008-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | NOVARTIS AG (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250242011-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | Seqirus UK Limited (GB) | 2025-07-31 | — | — | US | disclosed |
| CN-110475773-B | 8-Phenylisoquinoline and pharmaceutical composition thereof for treating irritable bowel syndrome | 琳达·佳慧·余 | 2025-06-24 | — | — | CN | disclosed |
| US-20240342267-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | SEQIRUS UK LTD (GB) | 2024-10-17 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| EP-3589626-B1 | 8-PHENYL-ISOQUINOLINES AND PHARMACEUTICAL COMPOSITION THEREOF USED IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME | UNIV NAT TAIWAN (TW) | 2024-06-12 | — | — | EP | disclosed |
| EP-4144369-A1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | Seqirus UK Limited (GB) | 2023-03-08 | — | — | EP | disclosed |
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | NATIONAL TAIWAN UNIVERSITY (TW) | 2022-11-22 | — | — | US | disclosed |
| US-11406701-B2 | Vaccination of immunocompromised subjects | Seqirus UK Limited (GB) | 2022-08-09 | — | — | US | disclosed |
| EP-3197487-B1 | VACCINATION OF IMMUNOCOMPROMISED SUBJECTS | SEQIRUS UK LTD (GB) | 2022-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558412-B2 | Vaccination of immunocompromised subjects | ICOS, IL15, CD4 | HTR7 4035/4885DRD2 3933/4885HTR1D 3624/4885 |
| US-11505529-B2 | 8-phenyl-isoquinolines and pharmaceutical composition thereof used in the treatment of irritable bowel syndrome | HTR7, GPR27, HTR5A | HTR7 1/4885DRD2 383/4885HTR1D 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.